Literature DB >> 27816260

The ABCC2 c.-24C>T polymorphism increases the risk of resistance to antiepileptic drugs: A meta-analysis.

Long Qian1, Shu Fang1, Yuan-Liang Yan1, Shuang-Shuang Zeng1, Zhi-Jie Xu2, Zhi-Cheng Gong3.   

Abstract

Several studies examined a possible link between multidrug resistance-associated protein 2 (ABCC2) gene variants and the risk of resistance to antiepileptic drugs (AEDs) in epilepsy, but the results were contradictory. In this study, a meta-analysis was conducted to assess the relevance of ABCC2 common variants (c.-24C>T, c.1249G>A, c.3972C>T) with the response risk of AEDs. We searched Embase, PubMed, the Cochrane Library and CNKI databases for case-control studies published through May 2016 that evaluated the role of ABCC2 gene variants in pharmacoresistance to AEDs. Odds ratios (ORs) and their 95% confidence intervals (CIs) were calculated to assess the strength of associations between the ABCC2 c.-24C>T, c.1249G>A and c.3972C>T variants and the risk of resistance to AEDs using an allele frequency model, dominant model and recessive model. Subgroup analyses were performed by ethnicity and the definition of drug-resistance. A total of 13 published studies involving 4300 patients (2261 patients with drug-resistant epilepsy and 2039 controls with drug-responsive epilepsy) met the selection criteria. We observed that the variant c.-24C>T was associated with a significantly increased risk of AED resistance (TT+CT vs CC: OR=1.24, 95%CI=1.06-1.46, p=0.009; TT vs CT+CC: OR=1.90, 95%CI=1.31-2.76, p=0.0008; T vs C: OR=1.27, 95%CI=1.11-1.46, p=0.0006). However, we identified no significant association of the ABCC2 c.1249G>A, c.3972C>T variants and haplotypes with the response to anticonvulsant drug in the overall population. In summary, these observations suggest that the ABCC2 c.-24C>T polymorphism is a likely risk factor for resistance to AEDs.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ABCC2; Antiepileptic drugs; Epilepsy; Meta-analysis; Polymorphism

Mesh:

Substances:

Year:  2016        PMID: 27816260     DOI: 10.1016/j.jocn.2016.10.014

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  7 in total

1.  Association between two SCN1A polymorphisms and resistance to sodium channel blocking AEDs: a meta-analysis.

Authors:  Yi Bao; Xinzhu Liu; Zheng Xiao
Journal:  Neurol Sci       Date:  2018-03-26       Impact factor: 3.307

2.  Effects of AQP4 and KCNJ10 Gene Polymorphisms on Drug Resistance and Seizure Susceptibility in Chinese Han Patients with Focal Epilepsy.

Authors:  Haoyue Zhu; Mengqi Zhang; Yujiao Fu; Hongyu Long; Wenbiao Xiao; Li Feng; Bo Xiao; Luo Zhou
Journal:  Neuropsychiatr Dis Treat       Date:  2020-01-09       Impact factor: 2.570

3.  Implications of genetic variation of common Drug Metabolizing Enzymes and ABC Transporters among the Pakistani Population.

Authors:  Nasir Ali Afsar; Henrike Bruckmueller; Anneke Nina Werk; Muhammad Kashif Nisar; H R Ahmad; Ingolf Cascorbi
Journal:  Sci Rep       Date:  2019-05-13       Impact factor: 4.379

4.  Comparison of oxcarbazepine efficacy and MHD concentrations relative to age and BMI: Associations among ABCB1, ABCC2, UGT2B7, and SCN2A polymorphisms.

Authors:  Xue Yang; Yuanliang Yan; Shu Fang; Shuangshuang Zeng; Hongying Ma; Long Qian; Xi Chen; Jie Wei; Zhicheng Gong; Zhijie Xu
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.889

Review 5.  A complex systems view on the current hypotheses of epilepsy pharmacoresistance.

Authors:  Gabriel Servilha-Menezes; Norberto Garcia-Cairasco
Journal:  Epilepsia Open       Date:  2022-03-11

Review 6.  Drug-Resistant Epilepsy: Multiple Hypotheses, Few Answers.

Authors:  Fei Tang; Anika M S Hartz; Björn Bauer
Journal:  Front Neurol       Date:  2017-07-06       Impact factor: 4.003

Review 7.  Pharmacogenetics of Carbamazepine and Valproate: Focus on Polymorphisms of Drug Metabolizing Enzymes and Transporters.

Authors:  Teresa Iannaccone; Carmine Sellitto; Valentina Manzo; Francesca Colucci; Valentina Giudice; Berenice Stefanelli; Antonio Iuliano; Giulio Corrivetti; Amelia Filippelli
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.